EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2022 • PDS Biotechnology Corp • Pharmaceutical preparations • Delaware
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective March 14, 2022 (the “Effective Date”), by and between Matthew Hill (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”), as an replacement of the Employment Agreement dated October 18, 2021, by and between the Company and the Executive. Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desires to continue to employ Executive and, in connection with such employment, and the Parties wish to enter into this Agreement to govern the terms and conditions of the Executive’s continued employment with the Company.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • PDS Biotechnology Corp • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective March 14, 2022 (the “Effective Date”), by and between Frank K. Bedu-Addo (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”), as an amendment, restatement and continuation of the Employment Agreement dated October 11, 2018, by and between the Company and the Executive. Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desires to continue to employ Executive and, in connection with such employment, and the Parties wish to enter into this Agreement to govern the terms and conditions of the Executive’s continued employment with the Company.
OPTION AGREEMENTOption Agreement • March 31st, 2022 • PDS Biotechnology Corp • Pharmaceutical preparations • Georgia
This Option Agreement, effective as of the date last signed below (“Effective Date”), is entered by and between the University of Georgia Research Foundation, Inc., a Georgia non-profit corporation (“UGARF”), and PDS Biotechnology Corporation with a principal place of business at 25B Vreeland Road, Suite 300, Florham park NJ 07932 (“Licensee”). UGARF and Licensee may each be referred to individually as a “Party” or may together be referred to collectively as the “Parties.”
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE - SUBLICENSABLEPatent License Agreement • March 31st, 2022 • PDS Biotechnology Corp • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options.
